Certain pMMR colorectal cancer patients should undergo additional MSI-PCR testing to reduce the risk of misdiagnosing MSI-H and Lynch syndrome

某些pMMR结直肠癌患者应接受额外的MSI-PCR检测,以降低误诊为MSI-H和林奇综合征的风险。

阅读:2

Abstract

BACKGROUND: Microsatellite instability (MSI) status guides immunotherapy and Lynch syndrome (LS) screening. Given the 5-10% discordance rate between mismatch repair immunohistochemistry (MMR-IHC) and Microsatellite instability polymerase chain reaction (MSI-PCR), true high microsatellite instability (MSI-H) cases in proficient mismatch repair (pMMR) colorectal cancer (CRC) may miss critical interventions. This study investigates molecular pathological characteristics between concordant and discordant groups assessed by these two methods, aiming to reduce the risk of misdiagnosing MSI-H and LS. METHODS: The MMR-IHC and MSI-PCR were conducted respectively in 2910 CRC patients. Sanger sequencing identified the mutation status of KRAS, BRAF, and PIK3CA genes, and next-generation sequencing (NGS) detected LS-related genes. We compared the molecular pathological features between the pMMR&MSS and pMMR&MSI-H groups, as well as between the dMMR&MSI-H and dMMR&MSS groups. Eleven screening strategies for pMMR&MSI-H were formulated for pMMR patients. RESULTS: The consistency rate between the two methods was 96.8% (2816/2910), with a discordance rate of 3.2% (94/2910), comprising 43 cases in the pMMR&MSI-H group and 51 cases in the dMMR&MSS group. Germline mutations in LS-associated genes were detected in 36.4% (4/11) of the pMMR&MSI-H group but were absent in all 9 dMMR&MSS cases. Compared with the pMMR&MSS consistent group, the pMMR&MSI-H inconsistent group showed higher prevalence in patients with right colon (55.8% vs.20.3%), well-differentiated (18.8% vs.8.4%), and PIK3CA exon 20 (E20) mutations (30.0% vs.8.7%). Compared with the dMMR&MSI-H consistent group, the dMMR&MSS inconsistent group was more common in patients with rectum (49.0% vs. 15.2%), stage IV patients (23.5% vs. 8.3%), and PIK3CA E20 wild-type (97.8% vs. 82.4%). The strategy of supplemental MSI-PCR detection for the right colon pMMR patients could identify 55.8% (24/43) of pMMR&MSI-H patients. Adding the detection of patients with PIK3CA E20 mutation based on the right colon can increase the PMMR&MSI-H detection rate to 65.1% (28/43). CONCLUSION: We recommend supplemental MSI-PCR testing for pMMR CRC patients with right colon OR PIK3CA E20 mutation. For those with MSI-H results, subsequent NGS should be performed to identify germline mutations in LS-associated genes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。